Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eurelings, M.
Right arrow Articles by Notermans, N. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eurelings, M.
Right arrow Articles by Notermans, N. C.
Related Collections
Right arrow Peripheral neuropathy
Right arrow Chronic inflammatory demyelinating polyneuropathy
Right arrow All Oncology
NEUROLOGY 2005;64:2079-2084
© 2005 American Academy of Neurology

Malignant transformation in polyneuropathy associated with monoclonal gammopathy

M. Eurelings, MD, H. M. Lokhorst, MD, PhD, S. Kalmijn, MD, PhD, J.H.J. Wokke, MD, PhD and N. C. Notermans, MD, PhD

From the Department of Neurology, Rudolf Magnus Institute of Neuroscience (Drs. Eurelings, Wokke, and Notermans), Department of Hematology (Dr. Lokhorst), Julius Center for Health Sciences and Primary Care (Dr. Kalmijn), University Medical Center, Utrecht, The Netherlands.

Address correspondence and reprint requests to Dr. M. Eurelings, Department of Neurology, University Medical Center Utrecht, G03.228, PO Box 85500, 3508 GA Utrecht, The Netherlands; e-mail: m.eurelings{at}neuro.azu.nl

Objective: To assess the frequency of hematologic malignancies at diagnosis and to determine the incidence and predictors of malignant transformation during follow-up in patients with polyneuropathy associated with monoclonal gammopathy.

Methods: Potential predictors of malignant transformation from medical history, hematologic, neurologic, and laboratory examination performed each 6 months were evaluated by univariable and multivariable Cox proportional hazard analysis.

Results: Of 193 patients with polyneuropathy associated with monoclonal gammopathy, 17 patients had a hematologic malignancy at diagnosis. The incidence rate of malignant transformation in 176 patients without a malignancy at diagnosis was 2.7/100 patient years. Weight loss, progression of the polyneuropathy, unexplained fever or night sweats, and M-protein level were independent predictors.

Conclusions: Since hematologic malignancies occur frequently in polyneuropathy associated with monoclonal gammopathy, the authors suggest that all patients should be screened at diagnosis and subsequently during follow-up if malignant transformation is suspected.

M.E. is supported by the Netherlands Organization for Scientific Research (NWO), project no. 940–37–030.

Received January 3, 2005. Accepted in final form March 14, 2005.




This article has been cited by other articles:


Home page
 NeurologyHome page
J.M.F. Niermeijer, M. Eurelings, M. W. van der Linden, H. M. Lokhorst, H. Franssen, K. Fischer, L. L. Teunissen, L. H. van den Berg, F. Schobben, J. H.J. Wokke, et al.
Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy
Neurology, July 3, 2007; 69(1): 50 - 59.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.